STOCK TITAN

[Form 4] Strata Critical Medical, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Positive)
Form Type
4

Strata Critical Medical, Inc. reported an insider transaction by Co-CEO, General Counsel, and Director Melissa M. Tomkiel. On 10/22/2025, she exercised stock options (transaction code M) for 55,556 shares of Class A common stock at $0.18 per share and acquired the same number of shares.

After the transaction, she directly beneficially owned 1,270,372 shares. Her remaining derivative holdings included 304,738 stock options outstanding, originally exercisable from 05/07/2021 and expiring on 07/28/2030.

Strata Critical Medical, Inc. ha riferito una transazione interna da parte della Co-CEO, General Counsel e Direttrice Melissa M. Tomkiel. Il 22/10/2025, ha esercitato opzioni su azioni (codice di transazione M) per 55.556 azioni di Class A a $0,18 per azione e ha acquisito lo stesso numero di azioni.

Dopo la transazione, possedeva direttamente 1.270.372 azioni. Le sue restanti partecipazioni derivate comprendevano 304.738 opzioni azionarie in circolazione, originariamente esercitabili dal 07/05/2021 e in scadenza il 28/07/2030.

Strata Critical Medical, Inc. informó una transacción interna de la co-CEO, asesoría general y directora Melissa M. Tomkiel. El 22/10/2025, ejerció opciones sobre acciones (código de transacción M) por 55.556 acciones de Class A a $0.18 por acción y adquirió el mismo número de acciones.

Después de la transacción, poseía directamente 1,270,372 acciones. Sus participaciones derivadas restantes incluían 304,738 opciones sobre acciones pendientes, originalmente ejercitables desde el 05/07/2021 y con vencimiento el 28/07/2030.

Strata Critical Medical, Inc.는 공동 CEO 겸 법무담당 최고책임자이자 이사인 Melissa M. Tomkiel의 내부자 거래를 보고했습니다. 2025년 10월 22일, 그녀는 주식매수선택권(거래 코드 M)을 행사하여 Class A 보통주 55,556주를 주당 $0.18에 매입했고 같은 수의 주식을 취득했습니다.

거래 후 그녀는 직접 유리하게 보유한 주식이 1,270,372주였습니다. 남아있던 파생적 보유 현황에는 원래 2021년 5월 7일 행사 가능하고 2030년 7월 28일 만료되는 304,738 주식매수선택권이 포함되어 있었습니다.

Strata Critical Medical, Inc. a signalé une transaction d’initié par la co-PDG, conseil juridique et administratrice Melissa M. Tomkiel. Le 22/10/2025, elle a exercé des options d’achat d’actions (code de transaction M) pour 55 556 actions de l Class A à 0,18 $ par action et a acquis le même nombre d’actions.

Après la transaction, elle détenait directement 1 270 372 actions. Ses positions dérivées restantes comprenaient 304 738 options sur actions en cours, initialement exerçables à partir du 07/05/2021 et arrivant à expiration le 28/07/2030.

Strata Critical Medical, Inc. meldete eine Insider-Transaktion von Co-CEO, General Counsel und Director Melissa M. Tomkiel. Am 22.10.2025 hat sie Aktienoptionen (Transaktionscode M) über 55.556 Aktien der Class A Stammaktie zu 0,18 $ pro Aktie ausgeübt und dieselbe Anzahl Aktien erworben.

Nach der Transaktion besaß sie direkt nutzbringend 1.270.372 Aktien. Ihre verbleibenden derivativen Positionen umfassten 304.738 noch ausstehende Optionen auf Aktien, ursprünglich ausübbar ab dem 07.05.2021 und brachten am 28.07.2030 Ablauf.

Strata Critical Medical, Inc. أبلغت عن معاملة داخلية من قِبل الرئيسة التنفيذية المشاركة للمدير العام والمدير Melissa M. Tomkiel. في 22/10/2025، قامت بممارسة خيارات أسهم (رمز المعاملة M) لــ 55,556 سهمًا من Class A بسعر $0.18 للسهم نفسه من الأسهم.

بعد المعاملة، امتلكت مباشرةً 1,270,372 سهمًا. وكانت ممتلكاتها المشتقة المتبقية تشمل 304,738 خيارات أسهم قائمة، كانت قابلة لممارسة من 05/07/2021 وتنتهي صلاحيّتها في 28/07/2030.

Strata Critical Medical, Inc. 报告了由共同首席执行官、总法律顾问兼董事 Melissa M. Tomkiel 进行的内部交易。于 2025/10/22,她行使了股票期权(交易代码 M),共 55,556 股 Class A 普通股,股价为每股 $0.18,并获得同等数量的股票。

交易后,她直接受益拥有 1,270,372 股。她的剩余衍生持股包括仍在外的 304,738 股股票期权,原始可自 2021/05/07 行使,到 2030/07/28 到期。

Positive
  • None.
Negative
  • None.

Strata Critical Medical, Inc. ha riferito una transazione interna da parte della Co-CEO, General Counsel e Direttrice Melissa M. Tomkiel. Il 22/10/2025, ha esercitato opzioni su azioni (codice di transazione M) per 55.556 azioni di Class A a $0,18 per azione e ha acquisito lo stesso numero di azioni.

Dopo la transazione, possedeva direttamente 1.270.372 azioni. Le sue restanti partecipazioni derivate comprendevano 304.738 opzioni azionarie in circolazione, originariamente esercitabili dal 07/05/2021 e in scadenza il 28/07/2030.

Strata Critical Medical, Inc. informó una transacción interna de la co-CEO, asesoría general y directora Melissa M. Tomkiel. El 22/10/2025, ejerció opciones sobre acciones (código de transacción M) por 55.556 acciones de Class A a $0.18 por acción y adquirió el mismo número de acciones.

Después de la transacción, poseía directamente 1,270,372 acciones. Sus participaciones derivadas restantes incluían 304,738 opciones sobre acciones pendientes, originalmente ejercitables desde el 05/07/2021 y con vencimiento el 28/07/2030.

Strata Critical Medical, Inc.는 공동 CEO 겸 법무담당 최고책임자이자 이사인 Melissa M. Tomkiel의 내부자 거래를 보고했습니다. 2025년 10월 22일, 그녀는 주식매수선택권(거래 코드 M)을 행사하여 Class A 보통주 55,556주를 주당 $0.18에 매입했고 같은 수의 주식을 취득했습니다.

거래 후 그녀는 직접 유리하게 보유한 주식이 1,270,372주였습니다. 남아있던 파생적 보유 현황에는 원래 2021년 5월 7일 행사 가능하고 2030년 7월 28일 만료되는 304,738 주식매수선택권이 포함되어 있었습니다.

Strata Critical Medical, Inc. a signalé une transaction d’initié par la co-PDG, conseil juridique et administratrice Melissa M. Tomkiel. Le 22/10/2025, elle a exercé des options d’achat d’actions (code de transaction M) pour 55 556 actions de l Class A à 0,18 $ par action et a acquis le même nombre d’actions.

Après la transaction, elle détenait directement 1 270 372 actions. Ses positions dérivées restantes comprenaient 304 738 options sur actions en cours, initialement exerçables à partir du 07/05/2021 et arrivant à expiration le 28/07/2030.

Strata Critical Medical, Inc. meldete eine Insider-Transaktion von Co-CEO, General Counsel und Director Melissa M. Tomkiel. Am 22.10.2025 hat sie Aktienoptionen (Transaktionscode M) über 55.556 Aktien der Class A Stammaktie zu 0,18 $ pro Aktie ausgeübt und dieselbe Anzahl Aktien erworben.

Nach der Transaktion besaß sie direkt nutzbringend 1.270.372 Aktien. Ihre verbleibenden derivativen Positionen umfassten 304.738 noch ausstehende Optionen auf Aktien, ursprünglich ausübbar ab dem 07.05.2021 und brachten am 28.07.2030 Ablauf.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tomkiel Melissa M.

(Last) (First) (Middle)
C/O STRATA CRITICAL MEDICAL, INC.
31 HUDSON YARDS, 14TH FLOOR

(Street)
NEW YORK NY 10001

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Strata Critical Medical, Inc. [ SRTA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Co-CEO and General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
10/22/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A common stock, $0.0001 par value per share 10/22/2025 M 55,556 A $0.18 1,270,372 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $0.18 10/22/2025 M 55,556 05/07/2021 07/28/2030 Class A common stock, $0.0001 par value per share 55,556 $0 304,738 D
Explanation of Responses:
Remarks:
/s/ Melissa M. Tomkiel 10/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Blade Air Mobility Inc

NASDAQ:BLDE

BLDE Rankings

BLDE Latest News

BLDE Latest SEC Filings

BLDE Stock Data

374.17M
64.57M
11.01%
75.82%
2.54%
Airports & Air Services
Air Transportation, Nonscheduled
Link
United States
NEW YORK